HSBC Holdings
CTKB icon

HSBC Holdings’s Cytek Biosciences CTKB Stock Holding History

HSBC Holdings’s Portfolio CTKB Stock Details CTKB Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q3 		– Sell
-15,006
Closed -$52.1K – 2779
2025
Q2 		$52.1K Buy
15,006
+1,243
+9% +$4.14K ﹤0.01% 2929
2025
Q1 		$55.3K Sell
13,763
-355
-3% -$1.84K ﹤0.01% 2892
2024
Q4 		$92.5K Sell
14,118
-1,288
-8% -$7.67K ﹤0.01% 2902
2024
Q3 		$86K Buy
15,406
+1,699
+12% +$9.63K ﹤0.01% 2820
2024
Q2 		$75.4K Buy
13,707
+247
+2% +$1.48K ﹤0.01% 2779
2024
Q1 		$90.3K Buy
+13,460
New +$106K ﹤0.01% 2864

Other funds holding CTKB

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Focus Partners Wealth
Focus Partners Wealth Boston, Massachusetts $89.9B AUM 20.5% 1-Year Est. Return
TCM
Topline Capital Management Santa Monica, California $605M AUM 26.24% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
HA
HHLR Advisors Grand Cayman, Cayman Islands $1.67B AUM 7.53% 1-Year Est. Return
BCM
Brown Capital Management Baltimore, Maryland $704M AUM 6.25% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return
Dimensional Fund Advisors
Dimensional Fund Advisors Austin, Texas $481B AUM 30.42% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

HSBC Holdings's CTKB Position: Q3 2025 in Review

HSBC Holdings sold out of Cytek Biosciences (CTKB) in Q3 2025, closing a stake of 15,006 shares — an estimated $52.1K sold.

HSBC Holdings first reported a position in CTKB in Q1 2024 and held it in 6 quarters. The position peaked at $92.5K in Q4 2024. 153 funds tracked by Wall St. Rank hold CTKB as of Q3 2025.

  • HSBC Holdings reported no remaining Cytek Biosciences position as of Q3 2025 after selling out during the quarter.
  • HSBC Holdings sold 15,006 Cytek Biosciences shares in Q3 2025, an estimated $52.1K.
  • HSBC Holdings first reported a position in Cytek Biosciences in Q1 2024 and held it in 6 quarters.
  • HSBC Holdings's Cytek Biosciences position peaked at $92.5K in Q4 2024.
  • 153 funds tracked by Wall St. Rank held Cytek Biosciences as of Q3 2025.

Based on HSBC Holdings's 13F filing for Q3 2025, filed 13 Nov 2025.